Aridis Meets Primary and Secondary Endpoints in Cystic Fibrosis Clinical Trial

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) has met the primary and secondary endpoints in safety and pharmacokinetics in a Phase 2a clinical trial evaluating a treatment in cystic fibrosis (CF).

Aridis’ lead candidate, AR-501, has received Orphan Drug, Fast Track and Qualified Infectious Diseases Product designations in the United States, and Orphan Drug designation in Europe, as a potential treatment of CF-related lung infections.

Highlights

  • The study evaluated the safety and pharmacokinetics of three ascending doses of AR-501 administered as an inhaled aerosol in CF patients with Pseudomonas aeruginosa bacterial infections.
  • CF patients achieved high uptake of AR-501 in the respiratory tract, at levels that were more than 50-fold higher than required for inhibition of the target bacteria.
  • Inhaled delivery achieved more than 10-fold higher respiratory uptake of AR-501 than past clinical studies of intravenous (IV) AR-501, which resulted in lung function improvement and bacteria reduction.
  • AR-501 is being developed as a once-weekly inhaled medication that will be self-administered using a commercially available nebulizer device.

The study was conducted with funding support from the Cystic Fibrosis Foundation.

Share This Article

 

About the Author

Aridis Meets Primary and Secondary Endpoints in Cystic Fibrosis Clinical Trial

Editor Prism MarketView